Aerovate Therapeutics Income Statement

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Operating Revenue	0.74	0.83	0.57	1.11
Other Revenue	0.03	0.03	-	-
Revenue	0.78	0.86	0.57	1.11
Revenue Growth (YoY)	-29.87%	52.58%	-48.88%	-
Cost of Revenue	1.68	1.91	0.17	0.19
Gross Profit	-0.9	-1.04	0.4	0.92
Selling, General & Admin	3.77	3.27	2.01	2.27
Operating Expenses	3.85	3.35	2.08	2.35
Operating Income	-4.75	-4.4	-1.68	-1.43
Interest Expense	-0.09	-0.12	-0.14	-0.11
Earnings From Equity Investments	-0.01	-0.01	-	-
Pretax Income	-5.27	-4.52	-1.82	-1.54
Net Income	-5.27	-4.52	-1.82	-1.54
Net Income to Common	-5.27	-4.52	-1.82	-1.54
Shares Outstanding (Basic)	0	50	35	-
Shares Outstanding (Diluted)	0	50	35	-
Shares Change (YoY)	-	42.63%	-	-
EPS (Basic)	-125.62	-0.09	-0.05	-
EPS (Diluted)	-125.62	-0.09	-0.05	-
Free Cash Flow	-4.1	-4.51	-0.39	-0.82
Free Cash Flow Per Share	-97.67	-0.09	-0.01	-
Gross Margin	-115.90%	-120.72%	69.98%	83.07%
Operating Margin	-611.82%	-508.68%	-297.49%	-128.66%
Profit Margin	-678.07%	-523.15%	-321.48%	-138.59%
Free Cash Flow Margin	-527.20%	-521.88%	-69.44%	-74.22%
EBITDA	-4.67	-4.31	-1.64	-1.38
EBITDA Margin	-	-	-290.45%	-124.57%
D&A For EBITDA	0.09	0.08	0.04	0.05
EBIT	-4.75	-4.4	-1.68	-1.43
EBIT Margin	-	-	-297.49%	-128.66%
Revenue as Reported	0.78	0.86	0.57	1.11

Source: S&P Global Market Intelligence. Standard template. Financial Sources.